Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1868-1876

  Vaidyanathan, Ganesan ^a   Friedman, Henry S ^a   Affleck, Donna J ^a   Schottelius, Margaret ^b   Wester, Hans Jürgen ^b   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE OCTREOTATE[3 TYROSINE IODINE 131]; GLUCOSE OCTREOTIDE[3 TYROSINE IODINE 131]; OCTREOTATE[3 TYROSINE IODINE 131]; OCTREOTIDE[3 TYROSINE IODINE 131]; OCTREOTIDE[3 TYROSINE]; SOMATOSTATIN RECEPTOR; TOSYLCHLORAMIDE SODIUM; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MEDULLOBLASTOMA; NONHUMAN; NUDE MOUSE; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIOIODINATION; RAT; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CEREBELLAR NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; IODINE RADIOISOTOPES; MEDULLOBLASTOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OCTREOTIDE; PANCREATIC NEOPLASMS; RATS; RECEPTORS, SOMATOSTATIN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0037989830     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Tomlinson, F. H., Scheithauser, B. W., Meyer, F. B., Smithson, W. A., Shaw, E. G., Miller, G. M., and Groover, R. V. Medulloblastoma: I. Clinical, diagnostic, and therapeutic overview. J. Child. Neurol., 7: 142-155, 1992.
2. Friedman, H. S., Oakes, W. J., Bigner, S. H., Wikstrand, C. J., and Bigner, D. D. Medulloblastoma: tumor biological and clinical perspectives. J. Neuro-Oncol., 11: 1-15, 1991.
3. Jennings, M. T., Slatkin, N., D'Angelo, M., Ketonen, L., Johnson, M. D., Rosenblum, M., Creasy, J., Tulipan, N., and Walker, R. Neoplastic meningitis as the presentation of occult primative neuroectodermal tumors. J. Child Neurol., 8: 306-312, 1993.
4. Habrand, J. L., and De Crevoisier, R. Radiation therapy in the management of childhood brain tumors. Child's Nerv. Syst., 17: 121-133, 2001.
5. Jannoun, L., and Bloom, H. J. G. Long-term psychological effects in children treated for intracranial tumors. Int. J. Radiat. Oncol. Phys. Biol., 18: 747-753, 1990.
6. Lannering, B., Marky, I., Lundberg, A., and Olsson, E. Long-tern sequelae after pediatric brain tumors: their effects on disability and quality of life. Med. Pediar. Oncol., 18: 303-310, 1990.
7. Packer, R. J., Cogenm, P., Vezina, G., and Rorke, L. B. Medulloblastoma: clinical and biological aspects. J. Neuro-Oncol., 1: 232-250, 1999.
8. MacMillan, T. J. In vitro radiosensitivity of human medulloblastoma cell lines. J. Neuro-Oncol., 15: 91-92, 1993.
9. 3octrotide (DOTATOC): A pilot study in human gliomas. Clin. Cancer Res., 5: 1025-1033, 1999.
10. 131I-labled anti-tenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J. Clin. Oncol., 18: 3862-3872, 2000.
11. 131I-radiolabelled monoclonal antibodies. J. Neuro-Oncol., 38: 225-232, 1998.
12. 2: A case study. Cancer (Phila.), 91: 1809-1813, 2001.
13. Bourne, S., Pemberton, L., Moseley, R., Lashford, L. S., Coakham, H. B., and Kemshead, J. T. Monoclonal antibodies M340 and UJ181.4 recognize antigens associated with primative neuroectodermal tumours. Hybridoma, 8: 415-426, 1989.
14. 211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res., 54: 5414-5419, 1994.
15. Müller, H. L., Frühwald, M. C., Scheubeck, M., Rrendl, J., Warmuth-Metz, M., Sörensen, N., Kühl, J., and Reubi, J. C. A possible role for somatostatin receptor scintigraphy in the diagnosis and followup of children with medulloblastoma. J. Neuro-Oncol., 38: 27-40, 1998.
16. 2) in medulloblastoma: implications for diagnosis and therapy. Pediatr. Res., 45: 697-708, 1999.
17. Wester, H-J., Schottelius, M., Scheidhauer, K., Reubi, J-C., Wolf, I., and Schwaiger, M. Comparison of radioiodinated TOC. TOCA, and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur. J. Nucl. Med., 29: 28-38, 2002.
18. 3-octreotide by conjugation with carbohydrates. Bioconjug. Chem., 13: 1021-1030.
19. Albert, R., Marbach, P., Bauer, W., Briner, U., Fricker, G., Bruns, C., and Pless, J. SDZ CO 611: A highly potent glycated analog of somatostatin with improved oral activity. Life Sci., 53: 517-525, 1993.
20. 3] octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy Nucl. Med. Commun., 19: 283-288, 1998.
21. Friedman, H. S., Burger, P. C., Bigner, S. H., Trojanowski, J. Q., Brodeur, G. M., He, X. M., Wikstrand, C. J., Kurtzberg, J., Berens, M. E., and Halperin, E. C. Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am. J. Pathol., 130: 472-484, 1988.
22. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res., 58: 437-441, 1998.
23. Vaidyanathan, G., Affleck, D. J., Welsh, P., Srinivasan, A., Schmidt, M., and Zalutsky, M. R. Radioiodination and astatination of octreotide by conjugation labeling. Nucl. Med. Biol., 27: 329-337, 2000.
24. Froidevaux, S., Meier, M., Häusler, M., Mäcke, H., Beglinger, C., and Eberle, A. N. A microplate binding assay for the somatostatin type-2 receptor (SSTR2). J. Recept. Signal Transduct. Res., 19: 167-180, 1999.
25. 3-octreotide: clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors. Nucl. Med. Biol., 27: 809-813, 2000.
26. Kwekkeboom, D., Krenning, E. P., and de Jong, M. Peptide receptor imaging and therapy. J. Nucl. Med., 41: 1704-1713, 2000.
27. 90Y-DOTATOC), a radiolabelled somatostatin analogue. Clin. Oncol., 12: 121-123, 2000.
28. 3-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med., 20: 716-731, 1993.
29. Bakker, W. H., Breemann, W. A. P., deJong, M., Visser, T. J., and Krenning, E. P. Iodine-131 labeled octreotide: not an option for somatostatin receptor therapy. Eur. J. Nucl. Med., 23: 775-781, 1996.
30. O'Connor, M. K., Kvols, L. K., Brown, M. L., Hung, J. C., Hayostek, R. J., Cho, D. S., and Vetter, R. J. Dosimetry and biodistribution of a Iodine-123 labeled somatostatin analog in patients with neuroendocrine tumors. J. Nucl. Med., 33: 1613-1619, 1992.
31. Holtzman, E. Lysosomes, pp. 95-100. New York: Plenum Press, 1989.
32. Daghighian, F., Barendswaard, E., Welt, S., Humm, J., Scott, A., Willingham, M. C., McGuffie, E., Old, L. J., and Larson, S. M. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J. Nucl. Med., 37: 1052-1057, 1996.
33. 3] octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology, 136: 3698-3706, 1995.
34. 3]octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radioguided surgery. Proc. Assoc. Am. Physicians, 111: 63-69, 1999.
35. 3-octreotate. A new somatostatin analog with improved target tissue uptake. Nucl. Med. Biol., 26: 267-273, 1999.
36. Froidevaux, S., Heppeler, A., Eberle, A. N., Meier, A-M., Häusler, M., Beglinger, C., Béhé, M., Powell, P., and Mäcke, H. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid-somatostatin analogues for tumor diagnosis and internal therapy. Endocrinology, 141: 3304-3312, 2000.
37. 3] octrotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int. J. Cancer, 75: 406-411, 1998.
38. 1-octreotide in nude mice transplanted with a human carcinoid tumor. Nucl. Med. Biol., 28: 67-73, 2001.
39. Schloos, J., Raulf, F., Hoyer, D., and Bruns, C. Identification and pharmacological characterization of somatostatin receptors in rat lung. Br. J. Pharmacol., 121: 963-971, 1997.
40. Fehlmann, D., Langenegger, D., Schuepbach, E., Siehler, S., Feuerbach, D., and Hoyer, D. Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery. J. Physiol., 94: 265-281, 2000.
41. Kraus, J., Wöltje, M., Schönwetter, N., and Höllt, V. Alternative promoter usage and tissue specific expression of the mouse somatostatin receptor 2 gene. FEBS Lett., 428: 165-170, 1998.
42. Schuster, J. M., Garg, P. K., Bigner, D. D., and Zalutsky, M. R. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. Cancer Res., 51: 4164-4169, 1991.
43. Garg, P. K., Alston, K. L., Welsh, P. C., and Zalutsky, M. R. Enhanced binding and inertness to dehalogenation of "-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjug. Chem., 7: 233-239, 1996.
44. Zalutsky, M. R., and Vaidyanathan, G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted α particle therapy. Curr. Pharm. Des., 6: 1433-1455, 2000.